Publications by authors named "E M Romero-Tejeda"
A sensitive and efficient analytical process for detecting lamotrigine in acidic solution based in ultra-high-performance liquid chromatography-diode array detector (UPLC-DAD) was developed; the stationary phase used was a C8, 150 × 4.6 mm, 2.6 m.
View Article and Find Full Text PDFArticle Synopsis
- There is a high rate of treatment failure with leflunomide (LEF) in rheumatoid arthritis (RA) patients, prompting this study to assess the effectiveness of teriflunomide levels (A77 1726) in predicting disease activity outcomes.
- The study involved comparing RA patients with low disease activity (DAS28-ESR ≤ 3.2) against those with moderate/severe disease activity (DAS28-ESR > 3.2) after LEF treatment in a sample of 115 patients.
- Results indicated that higher A77 1726 levels correlated negatively with disease activity, enabling high sensitivity and specificity in identifying patients who achieved better outcomes, thus showcasing its potential as a useful biomarker
Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America.
CPT Pharmacometrics Syst Pharmacol
April 2019
What Is Known And Objective: CYP2C19 genotypes presumably allow the prediction of the metabolizer phenotypes: poor (PMs), extensive (EMs) and ultra-rapid (UMs). However, evidence from previous studies regarding this predictive power is unclear, which is important because the benefits expected by healthcare institutions and patients are based on this premise. Therefore, we aimed to complete a formal evaluation of the diagnostic value of CYP2C19 and CYP3A4 genes for predicting metabolizer phenotypes established by omeprazole (OME) administration in 118 healthy children from Jalisco (western Mexico).
View Article and Find Full Text PDFAims: The aims of this study were (i) to develop a population pharmacokinetic (PK) model of tacrolimus in a Mexican renal transplant paediatric population (n = 53) and (ii) to test the influence of different covariates on its PK properties to facilitate dose individualization.
Methods: Population PK and variability parameters were estimated from whole blood drug concentration profiles obtained at steady-state using the non-linear mixed effect modelling software NONMEM® Version 7.2.